External Validation with Only One Hundred Patients

Abstract

A central question for immune-state and tumor evidence synthesis is not simply whether an output is accurate, but whether it survives scrutiny of validation precision. This literature-based conceptual analysis does not report a new experiment. The focal evidence concerns why autoimmune activity can persist or recur when conventional inflammation suppression does not durably change underlying cellular and tissue states. A validation sample can be geographically independent yet statistically imprecise. Event counts, subgroup sizes, and threshold uncertainty matter as much as the presence of a second center. Report uncertainty by subgroup and operating threshold. Avoid stable-looking conclusions for sparse strata and plan prospective evaluation around the required precision. The proposed comparison concerns two centers, subgroup events, calibration estimates; it would test whether the specific failure scenario is detected without erasing legitimate uncertainty. An integrated account should preserve the distinction between tissue contexts, clinical endpoints, and mechanistic claims and any stronger downstream decision.